• 1
    Davidson MB, Hix JK, Vidt DG, Brotman DJ. Association of impaired diurnal blood pressure variation with a subsequent declinein glomerular filtration rate. Arch Intern Med. 2006;166:846852.
  • 2
    Liu M, Takahashi H, Morita M, et al.Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in haemodialysis patients. Nephrol Dial Transplant. 2003;18:563569.
  • 3
    Torbjornsdotter TB, Jaremkl GA, Berg UB. Nondipping and its relation to glomerulopathy and hyperfiltration in adolescents with type 1 diabetes. Diabetes Care. 2004;27:510516.
  • 4
    Tamura K, Kanaoka T, Ohsawa M, et al.Emerging concept of anti-hypertensive therapy based on ambulatory blood pressure profile in chronic kidney disease. Am J Cardiovasc Dis.2011;1:236243.
  • 5
    Hermida RC, Ayala DE, Fontao MJ, Mojón A, Fernández JR. Chronotherapy with valsartan/amlodipine fixed combination: improved blood ressure control of essention hypertension with bedtime dosing. Chronobiol Int.2010;27:12871303.
  • 6
    Hermida RC, Ayala DE, Mojón A, Fontao MJ, Fernández JR. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. Chronobiol Int.2011;28:601610.
  • 7
    Hermida RC, Ayala DE, Chayan L, Mojón A, Fernández JR. Administration-time-dependent effects of olmesartan of the ambulatory blood pressure of essential hypertension patients. Chronobiol Int.2009;26:6179.
  • 8
    Minutolo R, Gabbai FB, Borrelli S, et al.Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. Am J Kidney Dis. 2007;50:908917.
  • 9
    National Kidney Foundation. K/DOQI clinical practice guidelines on chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;3:S1S266.
  • 10
    Mancia G, De Baker G, Dominiczak A, et al.2007 guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:11051187.
  • 11
    Schiller NB, Shah PM, Crawford M, et al.Recommendations for quantification of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr.1989;2:358367.
  • 12
    Zoccali C, Benedetto FA, Mallamaci F, et al.Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol. 2001;12:27682774.
  • 13
    Ommen SR, Nishimura RA. A clinical approach to the assessment of left ventricular diastolic function by Doppler echocardiography: update 2003. Heart. 2003;89:1823.
  • 14
    Ravera M, Re M, Deferrari L, Vettoretti S, Deferrari G. Importance of blood pressure cntrol in chronic kidney disease. J Am Soc Nephrol. 2006;17:S98S103.
  • 15
    Hermida RC, Carlos C, Ayala DE, et al.Administration time–dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension. 2003;42:283290.
  • 16
    Hermida RC, Ayala DE, Mojón A, Fernández JR. Reduction of morning blood pressure surge after treatment with nifedipine GITS at bedtime, but not upon awakening, in essential hypertension. Blood Press Monit.2009;14:152159.
  • 17
    Pogue V, Rahman M, Lipkowitz M, et al.Disparate estimates of hypertension control from ambulatory and clinicical blood pressure measurements in hypertensive kidney disease. Hypertension. 2009;53:2027.
  • 18
    Hermida RC, Calvo C, Ayala DE, López JE. Decrease in urinary albumin excretion associated to the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension. 2005;46:960968.
  • 19
    Hermida RC, Ayala DE, Mojón A, Fernández JR. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol. 2011;22:23132321.